2Abrams JS,Vena DA,Baltz J,et al.Paclitaxel activity in heavily pretreated breastcancer:a National Cancer Institute Treatment Referral Center Trial[J].J ClinOncol,1995,13:2056-2058.
3Seidman AD,Reichman BS,Crown JPA,et al.Paclitaxel as second and subsequent therapyfor metastatic breast cancer:Antivity independent of prior anthracycline response[J].JClin Ocol,1995,13:1152-1154.
4Ravdin PM,Burris HA,Cook G,et al.Phase II trial of docetaxel in advancedanthracycline-resistant or anthracenedione-resistant breast cancer[J].J ClinOncol,1995,13:2879-2882.
5Valero V,Holmes FA,Walters RS,et al.Phase II trial of docetaxel:a new, highlyeffective antineoplastic agent in the management of patients with anthracycline-resistantmetastatic breast cancer[J].J Clin Oncol,1995,13:2886-2890.
6Guastalla JP,Bonneterre J,Fumoleau P,et al.A phase II trial of docetaxel inpatients with anthracycline resistant metastatic breast cancer[J].Eur JCancer,1995,31(Suppl.5):75-78.
7Ten Bokkel Huinink W,Dubbelman R,Hiemstra A,et al.Phase I study of docetaxelalternating with epirubicin and cyclophosphamide in an escalated and accelerated scheduleby the concomitant use of lenograstim[J].Proc Annu Meet Am Soc ClinOncol,1996,15:141-144.
8Henderson IC,Hayes DF,Gelman R,et al.Dose reponse in the treatment of breastcancer:a critical review[J].J Clin Oncol,1988,6:1501-1503.
9Bezwoda WR,Dansey R,Seymour L.High-dose 4-epiadriamycin for treatment of breastcancer refractory to standard dose anthracycline chemotherapy;achievement of secondresposes[J].Oncology,1990,47:4-8.
